A recent Phase II clinical trial suggests that psilocybin, a hallucinogenic chemical in certain Psilocybe mushrooms, might offer significant benefits to cancer patients suffering from major depression.
This groundbreaking study, reported in Cancer, indicates that psilocybin therapy not only lessens depressive symptoms but also receives high praise from patients.
Psilocybin binds to serotonin receptors in the brain, altering mood, cognition, and perception.
Despite its current classification as a Schedule I drug with no accepted medical use in the U.S., recent research, including randomized controlled trials, has highlighted its safety and potential efficacy.
Psilocybin-assisted therapy, combining the drug with psychological support, shows promise in treating major depressive disorder and is being investigated for other mental health issues like anxiety, addiction, and PTSD.
In the Sunstone Therapies-conducted trial in Rockville, Maryland, 30 adults with cancer and major depression received a single 25 mg dose of synthetic psilocybin alongside therapist support and group therapy.
Unique to this study was its group-based approach. Patients were treated in cohorts with individual rooms but shared preparation and post-therapy integration sessions, facilitating a collective healing experience.
Participants initially had moderate to severe depression. After eight weeks, their depression scores significantly dropped, with many no longer showing depressive symptoms.
An impressive 80% of participants had a sustained response to the treatment, and 50% achieved full remission of symptoms after just one week, lasting for the trial’s duration. Side effects like nausea and headache were generally mild.
Dr. Manish Agrawal, the study’s lead author, highlighted the holistic potential of this therapy, particularly for cancer patients grappling with the psychological impacts of their illness. However, given the study’s small size and open-label nature, he notes the need for more extensive research.
A second study by Dr. Yvan Beaussant of Dana-Farber Cancer Institute focused on patients’ experiences.
Through exit interviews, participants expressed overwhelmingly positive sentiments about their therapy, emphasizing the importance of the structured, supportive setting.
They felt that the combination of individual and group sessions enhanced their treatment experience, fostering self-transcendence and compassion.
Dr. Beaussant, reflecting on the participants’ transformative journeys, noted the lasting positive impact on their lives and well-being, particularly in coping with cancer and, for some, the end of life.
Before psilocybin-assisted therapy can be integrated into clinical practice, further research is needed. Future studies should involve larger patient groups and a control arm to compare its effects with standard treatments or placebo.
This research marks a significant step towards understanding psilocybin’s potential as a therapeutic tool for cancer patients with depression, offering hope for a more holistic approach to cancer care.
If you care about cancer, please read studies that low-carb diet could increase overall cancer risk, and new way to increase the longevity of cancer survivors.
For more cancer information, please see recent studies about how to fight cancer with these anti-cancer superfoods, and results showing daily vitamin D3 supplementation may reduce cancer death risk.
Copyright © 2023 Knowridge Science Report. All rights reserved.
